12 / 25
PCOS 2018
Journal of Clinical and Molecular Endocrinology
ISSN: 2572-5432
Page 40
June 07-08, 2018
London, UK
4
th
World Congress on
Polycystic Ovarian
Syndrome
N
o consistent association between polycystic ovary syndrome
(PCOS) and risk for breast cancer (BC) was observed in a
recent systematic review, although it “incorrectly” reported that
“no consistent association between PCOS risk and breast cancer
was observed”. However, long-term use of oral contraceptives
(OC) is considered a first line therapy for PCOS and their
possible association to BC could be a concern in the informed
consent process. In the most recent publication of UpToDate, it
is stated as, “a non-significant increase (of BC) in ever users of
OCs compared with nonusers”. However, the latter conclusion
of a related meta-analysis of prospective cohort studies is
connected with an irrelevant reference and more importantly the
original paper states that “this meta-analysis provides evidence
of a non-significant increase in BC risk associated with ever OC
use, but the risk for long-term OC users is significantly greater”.
Furthermore, two major meta-analyses are totally ignored in this
publication: 1. The collaborative group on hormonal factors in BC
meta-analysis which suggested, “a causal relationship between
OC use and BC”, and 2. A meta-analysis of case-control studies
which concluded that “use of OCs is associated with an increased
risk of premenopausal BC, especially with use before first full-
term pregnancy in parous women”. For a reliable sharing decision
with the patient, the accuracy and sufficiency of information is
always very important.
giatrakis@teiath.grPCOS, oral contraceptives and the accuracy of information
Georgios Iatrakis
Athens University of Applied Sciences, Greece
J Clin Mol Endocrinol 2018, Volume 3
DOI: 10.21767/2572-5432-C1-003